Lung cancer

Lung cancer
#Immunotherapy #Lung cancer #Oncology #Preclinical investigations #The Francis Crick Institute

Triple combination treatment shrinks lung cancer tumours in mice

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have shown that a combination of treatments in mice with lung cancer allow immunotherapies to target non-responsive tumours. Their findings show that targeting tumours in different ways simultaneously might increase response to treatments. Read More

#Editor's Choice #News

Lungs
#Boehringer Ingelheim #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Over 60% response in lung cancer tumours with rare mutation

Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More

#Cancer Research #News #Trending News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights podcast: 2 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine… Read More

#News

Non-small cell lung cancer
#European Commission #Lung cancer #Oncology #Phase II trial #Pierre Fabre

EC approves new combination treatment for NSCLC

The European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. The EC decision followw a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on 25… Read More

#News #Regulatory

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights vodcast: 2 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   With the launch of an… Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

This week in drug discovery (26-30 August) 

News round-up for 26-30 August by DDW Senior Digital Content Editor Diana Spencer. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine announced this week, our news highlights focus on clinical trials, including studies of a monoclonal antibody and small molecule GLP-1 agonist for… Read More

#News

Non-small cell lung cancer
#FDA #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

FDA approves combination therapy for non-small lung cancer

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). It is approved in NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations,… Read More

#News #Regulatory

Non-small cell lung cancer
#Checkpoint inhibitor therapies #iOnctura #Lung cancer #Non-small cell lung cancer (NSCLC) #Phase II trial

Cancer ‘master switch’ study expands to lung cancer

iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC). Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in a Phase II study in combination with dostarlimab in patients with NSCLC… Read More

#Cancer Research #News

#Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #University of California

Genetically engineered dendritic cells enhance lung cancer therapy

A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response. When tested in mice with non-small cell lung cancer (NSCLC), the team discovered… Read More

#Cancer Research #News

T cells attacking cancer
#CAR-T #Elicera Therapeutics #Lung cancer #Oncology #Partnership #Skin cancer #T cell receptor (TCR)

Collaborators investigate novel T-cell receptor therapy

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer. Elicera Therapeutics will make parts of its technology iTANK available to… Read More

#Cancer Research #News

Non-small cell lung cancer
#AstraZeneca #FDA #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Combination therapy reduced risk of lung cancer progression by 38%

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). It is approved in combination with platinum-based chemotherapy for patients with la/mNSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. Efficacy… Read More

#News #Regulatory

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

New DDW Highlights podcast: 29 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the same week that it was revealed that breast cancer was the most… Read More

#News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

This week in drug discovery (22-26 January) 

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal,… Read More

#News

Non-small cell lung cancer
#Lung cancer #MHRA #Mirati Therapeutics #Non-small cell lung cancer (NSCLC) #Oncology #UK

MHRA approves drug for lung cancer with limited therapy options

The UK regulator has approved a new treatment for non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C. The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Krazati (adagrasib) to treat patients whose disease is advanced or has spread… Read More

#News #Regulatory